Search clinical trials for: relapsed

Total 5283 results

National Cancer Institute (NCI)

Completed

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Pfizer

Completed

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Neoplasms | Adenocarcinoma

United States, France, Russian Federation, Canada, Germany, Mexico, Poland
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoma | Leukemia

United States
University of Arkansas
National Cancer Institute (NCI)

Completed

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Multiple Myeloma and Plasma Cell Neoplasm

United States
Charite University, Berlin, Germany
Deutsche Kinderkrebsstiftung

Completed

ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia

Lymphoma, Non-Hodgkin | Lymphoblastic Leukemia, Acute

Germany
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Leukemia

United States, Canada, Australia
Roswell Park Cancer Institute

Terminated

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
Genentech, Inc.

Terminated

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Centocor, Inc.

Withdrawn

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Belgium, Poland, Bulgaria, Turkey, Ukraine, Australia, Korea, Republic of, New Zealand, Czech Republic, United Kingdom, Netherlands, India
National Cancer Institute (NCI)

Terminated

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma

United States
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Secondary Acute Myeloid Leukemia | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia

United States
University of Southampton
University Hospital Southampton NHS Foundation Trust

Unknown

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors (GemTIP)

Testicular Germ Cell Tumor | Ovarian Cancer | Brain and Central Nervous System Tumors | Extragonadal Germ Cell Tumor

United Kingdom
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Cardiac Toxicity

United States
National Cancer Institute (NCI)

Completed

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Embryonal-botryoid Childhood Rhabdomyosarcoma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Grade III Lymphomatoid Granulomatosis | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small... and other conditions

United States
University of Copenhagen

Completed

Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients

Dental Caries

Sweden
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular... and other conditions

United States
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Multiple Myeloma

Australia
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Completed

Phase I Study in RAD 001 Patients With Relapse AML

AML

France
Infinity Pharmaceuticals, Inc.

Completed

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Proacta, Incorporated

Terminated

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Lung Cancer

United States
Bristol-Myers Squibb

Completed

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma (MDX1401-01)

Hodgkin's Lymphomas

United States
Azad University of Medical Sciences

Completed

Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy

Mucositis | Infection | Dry Mouth

Iran, Islamic Republic of
GlaxoSmithKline

Completed

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Ovarian Cancer | Neoplasms, Ovarian

United States, Canada
Piramal Enterprises Limited

Completed

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

India
Abbott

Completed

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Solid Tumor Cancers

United States
Assistance Publique - Hôpitaux de Paris

Terminated

Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma (ITOV04)

Ovarian Cancer | Relapses

France
Korea Cancer Center Hospital

Unknown

A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Relapsed or Refractory Diffuse Large B Cell Lymphoma

Korea, Republic of
NYU Langone Health
National Cancer Institute (NCI)

Completed

R115777 in Treating Patients With Relapsed Small Cell Lung Cancer

Lung Cancer

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)

Spain
M.D. Anderson Cancer Center

Withdrawn

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Lymphoma | Leukemia

Search clinical trials for: relapsed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations